Humanized antibody produces marked improvement in plaque psoriasis

Washington - The humanized monoclonal antibody efalizumab, given once weekly subcutaneously, produces profound clinical improvement in moderate to severe plaque psoriasis, reported Craig Leonardi, M.D., at the American Academy of Dermatology's 59th annual meeting.